genetic-medicines
(4)
Shehnaaz Suliman built a career by changing the scale of the problem
From Cape Flats protests to Oxford, Wall Street and the biotech boardroom, Suliman kept asking one question: how can one decision reach more people?
Chris McNulty
Chris McNulty is the interim CEO of Ring Therapeutics, a Cambridge, Massachusetts biotech developing genetic medicines that use commensal anelloviruses as delivery vectors. An MIT-trained engineer with a Harvard MBA, he joined Ring in May 2023 as Chief Financial Officer and Head of Corporate Strategy and stepped up to lead the company in December 2024. Over more than 15 years in pharma and biotech finance, he has closed financing transactions worth more than $300 million across companies including VBI Vaccines, InVivo Therapeutics, Repligen, and Genzyme.
Christian Cobaugh
Christian Cobaugh is a molecular biologist turned biotech operator who has spent more than 15 years at the frontier of genetic medicines. In January 2026 he became CEO of Alloy Genetic Medicines, the nucleic-acid division of Alloy Therapeutics, where he leads work on the AntiClastic cyclic nucleic acid platform for ASOs, siRNA, and other RNA therapeutics. He is best known for founding Vernal Biosciences, an mRNA contract manufacturer he built in Colchester, Vermont, on the premise that everyone who needs mRNA should be able to get it. Before Vernal he was the first scientist in the Alexion-Moderna mRNA partnership and held discovery, development, and manufacturing roles at Arcturus Therapeutics, CRISPR Therapeutics, Translate Bio, and Omega Therapeutics.
Kunwoo Lee
Kunwoo Lee is the CEO and Co-founder of BreezeBio (formerly GenEdit), a Brisbane, California-based biotech company pioneering non-viral gene delivery through its proprietary NanoGalaxy platform. A Siebel Scholar and Forbes 30 Under 30 honoree who earned his PhD from UC Berkeley-UCSF Joint Program in Bioengineering, Lee co-founded GenEdit in 2016 alongside Professor Niren Murthy and fellow researcher Hyo Min Park, building out a polymer nanoparticle library of thousands of chemically distinct compounds capable of delivering diverse genetic payloads to specific tissues. The company has raised over $118 million including a $60M Series B in February 2026, struck a landmark $644M collaboration deal with Genentech, and rebranded to BreezeBio to signal its pivot from platform company to clinical-stage therapeutics developer advancing BRZ-101 for Type 1 Diabetes.